Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Peter

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Rontgenpraxis; Zeitschrift Fur Radiologische Technik|March 20, 2009
[Weight bearing upright magnetic resonance imaging of pointe dancing]Oliver Peter Graber, Wolfgang Oberthaler
Klinische Monatsblatter Fur Augenheilkunde|January 28, 2004
[Frequency of reoperations after amniotic membrane transplantation]Oliver Peter Denk, Ulla Birk, Jörn Von Eicken, et al.
SLAS Technology|December 14, 2025
Editorial: Robotics in laboratory automationKerstin Thurow, Oliver Peter, Patrick Courtney, et al.
Molecular and Biochemical Parasitology|March 19, 2002
Amino-terminal control of transgenic protein expression levels in Toxoplasma gondiiMariana Matrajt, Manami Nishi, Martin J Fraunholz, et al.
Nature|June 20, 2008
Crystal structure of the ligand-free G-protein-coupled receptor opsinJung Hee Park, Patrick Scheerer, Klaus Peter Hofmann, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotypeJulien Pothier, Markus A Riederer, Oliver Peter, et al.
SLAS Technology|March 28, 2025
An out-of-hours cell culture autopilot proof of concept based on a modular architecture using the SiLA2 open standardPatrick Courtney, Raphael Lieberherr, William Speed, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2013
Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffoldAnja Valdenaire, Julien Pothier, Dorte Renneberg, et al.
Journal of Medicinal Chemistry|June 1, 2013
Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonistHeinz Fretz, Anja Valdenaire, Julien Pothier, et al.
Chimia|October 27, 2017
The Screening Compound Collection: A Key Asset for Drug DiscoveryChristoph Boss, Julien Hazemann, Thierry Kimmerlin, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Rontgenpraxis; Zeitschrift Fur Radiologische Technik|March 20, 2009
[Weight bearing upright magnetic resonance imaging of pointe dancing]Oliver Peter Graber, Wolfgang Oberthaler
Klinische Monatsblatter Fur Augenheilkunde|January 28, 2004
[Frequency of reoperations after amniotic membrane transplantation]Oliver Peter Denk, Ulla Birk, Jörn Von Eicken, et al.
SLAS Technology|December 14, 2025
Editorial: Robotics in laboratory automationKerstin Thurow, Oliver Peter, Patrick Courtney, et al.
Molecular and Biochemical Parasitology|March 19, 2002
Amino-terminal control of transgenic protein expression levels in Toxoplasma gondiiMariana Matrajt, Manami Nishi, Martin J Fraunholz, et al.
Nature|June 20, 2008
Crystal structure of the ligand-free G-protein-coupled receptor opsinJung Hee Park, Patrick Scheerer, Klaus Peter Hofmann, et al.
Bioorganic & Medicinal Chemistry Letters|June 26, 2012
Novel 2-(2-(benzylthio)-1H-benzo[d]imidazol-1-yl)acetic acids: discovery and hit-to-lead evolution of a selective CRTh2 receptor antagonist chemotypeJulien Pothier, Markus A Riederer, Oliver Peter, et al.
SLAS Technology|March 28, 2025
An out-of-hours cell culture autopilot proof of concept based on a modular architecture using the SiLA2 open standardPatrick Courtney, Raphael Lieberherr, William Speed, et al.
Bioorganic & Medicinal Chemistry Letters|January 18, 2013
Evolution of novel tricyclic CRTh2 receptor antagonists from a (E)-2-cyano-3-(1H-indol-3-yl)acrylamide scaffoldAnja Valdenaire, Julien Pothier, Dorte Renneberg, et al.
Journal of Medicinal Chemistry|June 1, 2013
Identification of 2-(2-(1-naphthoyl)-8-fluoro-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)acetic acid (setipiprant/ACT-129968), a potent, selective, and orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2) antagonistHeinz Fretz, Anja Valdenaire, Julien Pothier, et al.
Chimia|October 27, 2017
The Screening Compound Collection: A Key Asset for Drug DiscoveryChristoph Boss, Julien Hazemann, Thierry Kimmerlin, et al.
Pageof 2